Evolocumab como tratamiento de la dislipemia secundaria a lorlatinib

  1. Laura Pérez Alonso 1
  2. Raquel Cervera Calero 1
  3. María Ángeles Campos Fernández de Sevilla 1
  4. Miguel Ángel Moreno Palanco 2
  5. Jorge Francisco Gómez Cerezo 2
  1. 1 Hospital Universitario del Henares, Madrid, España
  2. 2 Hospital Universitario Infanta Sofía, Madrid, España
Journal:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168,  1578-1879

Year of publication: 2023

Volume: 35

Issue: 2

Pages: 88-90

Type: Article

DOI: 10.1016/J.ARTERI.2022.12.003 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Clínica e investigación en arteriosclerosis

Abstract

Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer.

Data source: Dialnet